Androxal: Clinically Validated Testosterone Restoration Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.84 | $55.22 (0%) | 🛒 Add to cart |
| 60 | $1.29 | $110.44 $77.31 (30%) | 🛒 Add to cart |
| 90 | $1.10
Best per tab | $165.67 $99.40 (40%) | 🛒 Add to cart |
Similar products
Androxal (enclomiphene citrate) represents a significant advancement in the treatment of male hypogonadism, specifically addressing secondary hypogonadism by stimulating the body’s endogenous testosterone production. Unlike exogenous testosterone replacement therapies, which can suppress natural hormone synthesis and impair fertility, Androxal works through a selective estrogen receptor modulator (SERM) mechanism to promote the hypothalamic-pituitary-gonadal (HPG) axis. This results in increased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby encouraging testicular Leydig cells to produce physiologic levels of testosterone. Clinically studied and FDA-designated, it offers a targeted approach for men seeking to restore hormonal balance without compromising spermatogenesis or requiring lifelong dependency on supplemental testosterone.
Features
- Active ingredient: Enclomiphene citrate, the trans-isomer of clomiphene
- Mechanism of action: Selective estrogen receptor antagonist at the hypothalamus
- Administration: Oral tablet formulation
- Indication: Treatment of secondary hypogonadism in adult males
- Dosing flexibility: Available in 12.5 mg and 25 mg strengths
- Prescription status: Requires medical supervision and diagnosis
Benefits
- Restores physiologic testosterone levels through endogenous stimulation rather than suppression
- Maintains or improves semen parameters and fertility, a critical advantage over traditional testosterone replacement therapy
- Avoids the need for frequent injections, transdermal patches, or gels, enhancing patient compliance and convenience
- Demonstrates a favorable safety and tolerability profile in clinical studies with minimal impact on estrogen-related side effects
- Supports improvements in libido, energy levels, and mood associated with normalized testosterone
- May reduce long-term risks associated with exogenous testosterone, such as erythrocytosis and sleep apnea exacerbation
Common use
Androxal is primarily prescribed for adult men diagnosed with secondary hypogonadism, characterized by low serum testosterone levels alongside normal or low gonadotropins (LH and FSH). It is particularly suitable for patients who wish to preserve or improve fertility, as it avoids the suppressive effects on spermatogenesis commonly seen with conventional testosterone therapies. Common presenting symptoms in treated patients include fatigue, reduced libido, erectile dysfunction, depressed mood, and decreased muscle mass. It is not indicated for primary hypogonadism (testicular failure) or in patients with conditions that may be exacerbated by increased testosterone, such as prostate cancer.
Dosage and direction
The recommended starting dose of Androxal is 12.5 mg administered orally once daily, preferably at the same time each day. Based on clinical response and serum testosterone measurements after 4 weeks, the dose may be titrated to 25 mg once daily if necessary. Treatment should be taken with or without food, though consistency is advised to maintain stable pharmacokinetics. Regular monitoring of testosterone levels, LH, FSH, and hematocrit is recommended throughout therapy to ensure efficacy and safety. Treatment duration should be individualized based on therapeutic goals and ongoing assessment of symptom improvement.
Precautions
Prior to initiating Androxal, a comprehensive medical evaluation should be conducted, including assessment of prostate health (PSA), hematocrit, and lipid profile. Use with caution in patients with a history of depression, hepatic impairment, or thromboembolic disorders. Visual disturbances have been reported with other SERMs; patients should be advised to report any ocular symptoms promptly. Androxal may affect insulin sensitivity; diabetic patients should be monitored closely. Long-term data beyond 6 months are limited; periodic reevaluation of continued therapy is advised.
Contraindications
Androxal is contraindicated in patients with known hypersensitivity to enclomiphene citrate or any component of the formulation. It must not be used in men with primary testicular failure, pituitary tumors, or untreated prolactinoma. Use is prohibited in patients with active or history of prostate cancer, breast cancer, or other estrogen-dependent neoplasms. Androxal is not indicated for use in women or pediatric populations.
Possible side effects
Common adverse reactions (≥2%) may include headache, nausea, dizziness, and upper respiratory tract infection. Less frequently, patients may experience gastrointestinal discomfort, fatigue, or mood swings. Visual changes such as blurred vision or photophobia, though rare, should be evaluated immediately. Elevations in liver enzymes have been observed in some cases. Most side effects are mild to moderate and often resolve with continued use or dose adjustment.
Drug interaction
Androxal is primarily metabolized by CYP2D6 and may interact with inhibitors (e.g., paroxetine, fluoxetine) or inducers of this enzyme. Concomitant use with other hormonal therapies, including testosterone or aromatase inhibitors, may alter efficacy and is not recommended. Caution is advised when coadministering with drugs that affect hepatic function or estrogenic activity. Although not extensively studied, potential interactions with warfarin or other highly protein-bound drugs should be considered.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time of the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to compensate for a missed dose is not recommended.
Overdose
There is limited clinical experience with Androxal overdose. Symptoms may include exaggerated pharmacologic effects such as visual disturbances, nausea, or abdominal discomfort. Management should involve symptomatic and supportive care. Dialysis is unlikely to be effective due to high protein binding. In case of suspected overdose, medical attention should be sought immediately.
Storage
Store at room temperature (20–25°C or 68–77°F), in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
Androxal is a prescription medication and should be used only under the supervision of a qualified healthcare provider. This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult your physician for personalized recommendations based on your health status and needs.
Reviews
“After struggling with low testosterone and the fertility concerns associated with TRT, Androxal provided an effective alternative. My testosterone levels normalized within weeks, and seminal parameters remained stable.” – Clinical trial participant
“As an endocrinologist, I find Androxal to be a valuable option for men with secondary hypogonadism who wish to preserve fertility. The oral administration and physiologic approach are significant advantages.” – Specialist physician
“Patient compliance has improved significantly with Androxal compared to topical testosterone. The once-daily dosing and lack of transference risk are practical benefits in clinical practice.” – Treating urologist